ERBB2 and breast cancer: In the present study, we assessed the feasibility of enrolling untreated patients with stage II or III HR+/HER2-negative breast cancer to upfront experimental treatment with combined PD-L1/CTLA-4 checkpoint inhibition prior to standard NACT and surgery.